- Report
- March 2024
- 184 Pages
Global
From €3226EUR$3,374USD£2,772GBP
€3584EUR$3,749USD£3,080GBP
- Report
- August 2023
- 336 Pages
Global
From €5258EUR$5,500USD£4,518GBP
- Report
- July 2023
- 220 Pages
Global
From €1902EUR$1,990USD£1,635GBP
- Report
- December 2022
- 66 Pages
Global
From €3346EUR$3,500USD£2,875GBP
- Report
- March 2022
- 140 Pages
Global
From €1902EUR$1,990USD£1,635GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3442EUR$3,600USD£2,958GBP
- Report
- February 2024
- 70 Pages
Japan
From €4541EUR$4,750USD£3,902GBP
- Report
- March 2022
- 124 Pages
Global
From €4254EUR$4,450USD£3,656GBP
- Report
- August 2021
Europe
From €3270EUR$3,420USD£2,810GBP
- Report
- August 2021
Global
From €3815EUR$3,990USD£3,278GBP
- Report
- February 2022
- 62 Pages
Global
From €3346EUR$3,500USD£2,875GBP
- Drug Pipelines
- November 2020
- 1251 Pages
Global
From €2390EUR$2,500USD£2,054GBP
- Drug Pipelines
- June 2020
- 35 Pages
Global
From €1912EUR$2,000USD£1,643GBP
- Drug Pipelines
- September 2018
- 64 Pages
Global
From €3346EUR$3,500USD£2,875GBP
- Drug Pipelines
- June 2018
- 31 Pages
Global
From €3346EUR$3,500USD£2,875GBP
- Report
- April 2023
- 120 Pages
Global
€3346EUR$3,500USD£2,875GBP
- Report
- October 2022
- 1127 Pages
Global
From €2390EUR$2,500USD£2,054GBP
- Report
- July 2022
- 100 Pages
Global
From €3346EUR$3,500USD£2,875GBP
- Drug Pipelines
- October 2020
- 37 Pages
Global
From €3346EUR$3,500USD£2,875GBP
- Drug Pipelines
- October 2020
- 69 Pages
Global
From €3346EUR$3,500USD£2,875GBP
The Type 2 Diabetes Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. These drugs are used to treat Type 2 Diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin properly. Type 2 Diabetes Drugs are used to help control blood sugar levels, reduce the risk of complications, and improve overall health. These drugs can be taken orally, injected, or inhaled. Common Type 2 Diabetes Drugs include Metformin, Sulfonylureas, Thiazolidinediones, Meglitinides, DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors.
Some companies in the Type 2 Diabetes Drug market include Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, Boehringer Ingelheim, and Takeda. Show Less Read more